California Institute for Regenerative Medicine awarded Sangamo $6.4M to develop its ZFP-genome editing technology for the treatment of beta-thalassemia (加州再生醫學研究所授予Sangamo公司了$ 6.4M開發其 ZFP 基因組編輯技術治療β-地中海貧血)

How the technology work?




Figure 1: Schematic to demonstrate the position and orientation of binding of a ZFNs pair to a specific DNA sequence to enable generation of a double strand break in the DNA.




Figure 2: Schematic to demonstrate potential outcomes of a double-strand break in DNA generated by a pair of ZFNs, gene disruption, gene correction or DNA insertion.


Original Source: http://www.sangamo.com/technology/zf-nucleases.html